Centessa Pharmaceuticals plc
CNTA
Classement en actions
#2969
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical... Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.
Prix de l'action
$40.50
Dernière synchronisation: 2026-06-29
Capitalisation boursière
$6.22B
Changement (1 jour)
0.00%
Changement (1 an)
77.71%
Pays
GB
Échange Centessa Pharmaceuticals plc (CNTA)
Catégorie
Healthcare
Ratio P/E pour Centessa Pharmaceuticals plc (CNTA)
Ratio P/E au October 2026 TTM : -22.75
Selon les derniers rapports financiers et le cours de l'action de Centessa Pharmaceuticals plc, le ratio P/E actuel (TTM) est de -22.75. À la fin de l’année 2023, le P/E de l’entreprise était de -5.07.
Historique du ratio P/E pour Centessa Pharmaceuticals plc de 2019 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | -22.75 | 179.86% |
| 2024 | -8.13 | 60.50% |
| 2023 | -5.07 | 278.38% |
| 2022 | -1.34 | -98.59% |
| 2021 | -95.03 | -34.28% |
| 2020 | -144.60 | -67.01% |
| 2019 | -438.27 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| 28.78 | -226.50% |
US
|
|
| -28.36 | 24.64% |
US
|
|
| -24.57 | 7.97% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -233.30% |
NL
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.